Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

This trial is testing whether giving an immune checkpoint drug (pembrolizumab or a similar immunotherapy) before surgery — combined with a freezing treatment called cryoablation that destroys a portion of the tumor — can activate the immune system to fight triple-negative breast cancer more effectively. **You may be eligible if...** - You are a woman 18 years or older - You have been diagnosed with triple-negative breast cancer (meaning the tumor is negative for estrogen receptor, progesterone receptor, and HER2) - Your tumor is at least 1 cm in size and has not spread to distant organs - You are planning to have a mastectomy or lumpectomy - Your tumor can be targeted by the freezing (cryoablation) procedure - Your blood counts and organ function are within acceptable ranges - Your general health is good (ECOG score 0–1) **You may NOT be eligible if...** - Your breast cancer has spread to other parts of the body - Your tumor is too small or not accessible for cryoablation - You have serious immune-related conditions or are on high-dose immune-suppressing medications - Your blood counts or organ function are outside acceptable ranges Talk to your doctor to see if this trial is right for you.